← Home

HLS

Healthcare & BiotechDOWNTREND

$0.345

as of 2026-07-27

Who's been buying — 30 days

net $, conviction-weighted
NIBInvestment banks+$2.5M
WAWealth & advisers+$1.5M
RetailRetail · context+$1.5M
ResResource specialists+$640k
MMMarket makers+$182k

5d return

-4.2%

20d return

-11.5%

60d return

-30.3%

RSI 14

31.8

vs 52w high

-66.8%

vs 52w low

+9.5%

SMA 20

Below

SMA 50

Below

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.
Loading chart…
Closest correlates
Pearson r on log returns, window: 42d
  • LACr=0.39, window: 42d
  • CUVr=0.39, window: 42d
  • DEVr=0.38, window: 42d
  • PENr=0.37, window: 42d
  • GA8r=0.37, window: 42d
Announcements — last 30 days
  • 2026-07-10PSsubstantial_holderCeasing to be a substantial holder

    JPMorgan Chase divested below the 5% substantial holder threshold through securities lending unwinding and modest equity sales on 3–7 July. The exit follows a 15% share price run-up over 20 days, suggesting opportunistic de-risking rather than distressed selling.

  • 2026-07-07PSsubstantial_holderBecoming a substantial holder

    JPMorgan Chase and affiliates crossed the 5% threshold in Healius, predominantly via securities lending arrangements (90% of position) rather than outright ownership, signalling institutional passive accumulation or financing activity rather than strategic conviction. The heavy skew toward borrowed securities and minimal proprietary purchases suggests this is primarily a financing/lending operation rather than a vote-seeking takeover play.

  • 2026-07-07PSsubstantial_holderCeasing to be a substantial holder

    Vanguard exited its 5%+ stake in Healius (HLS) on 01 July 2026, reducing to 4.721% and triggering substantial holder notification. The exit appears orderly and spread over Q2–Q3 2026, suggesting rebalancing rather than distress.